W

ow. It’s Friday. This week was particularly interminable, wasn’t it? This is Meghana, by the way, subbing in for Ed by way of The Readout. (Sign up here!) As we ready ourselves for the glorious weekend, here’s a roundup of some notable pharma news:

Chinese scientists have used CRISPR to correct genetic mutations in a human embryo, New Scientist reports. Though the study focused on just six human embryos, it’s showing that CRISPR seems to work better in normal embryos than it did in previous tests on abnormal embryos that couldn’t develop into children. In related news, US scientists have made some major strides in synthetically assembling a complete yeast genome, STAT’s Sharon Begley reports.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy